HOPA 2025 BCOP-Only Bundle On-Demand

UAN#: 0465-0000-25-008-H01-P

Presenter:

• Madeline Ochs, PharmD, BCOP

Session Description:

This session will provide an overview of recently approved treatments and agents in the pipeline for the treatment of hemophilia, including ultra-long half-life factor VIII, non-factor therapy, and gene therapy. As a result of the expanding treatment armamentarium, prophylaxis considerations are shifting from what is feasible to what is most optimal, with individualization considering patient preferences, adherence, activity level, and efficacy/safety data. This session will provide an update on the various treatment modalities, their clinical efficacy and safety, and clinical pearls that can be used as considerations to guide optimal therapy selection.

Learning Objectives:

1. Review the historical treatment paradigm for hemophilia A and B
2. Describe the mechanisms of action of newly approved agents and those in the pipeline for the treatment of hemophilia A and B
3. Interpret safety and efficacy data for newly approved agents
4. Apply primary literature and patient-specific characteristics to the selection of treatment for patients with hemophilia A and B

UAN#: 0465-0000-25-018-H99-P

Presenters:

• Amber Cipriani, PharmD, BCOP
• Mark Zangardi, PharmD, BCOP, MS

Session Description:

In this session, the presenters will provide a background on the scientific and technological aspects of circulating tumor DNA (ctDNA) testing; reviewing current applications for ctDNA testing in cancer care; appraise recent clinical trial data on the use of ctDNA testing in various settings; discuss limitations, practical challenges, and unanswered questions related to ctDNA testing in routine clinical practice; and provide insight into future directions surrounding ctDNA testing across the cancer care continuum. The session will focus on how pharmacists can be involved in the selection and interpretation of ctDNA test results to inform treatment decisions and improve patient care.

Learning Objectives:

1. Describe circulating tumor DNA (ctDNA) testing technologies
2. Compare the benefits and limitations of ctDNA testing with tissue-based testing
3. Interpret the data using ctDNA to monitor for response or resistance to treatment in advanced cancer
4. Evaluate examples of the use of ctDNA to guide therapeutic decisions prior to and after local therapy in early stage solid tumors
5. Summarize the evidence for cancer early detection assays utilizing ctDNA technology

UAN#: 0465-0000-25-030-H01-P

Presenter:

• Bianka Patel, PharmD, BCOP, CPP

Session Description:

The treatment landscape of chronic lymphocytic leukemia (CLL) has evolved significantly over the last several years. This session will provide an overview of noteworthy updates, including novel combinations in the front-line setting and newer therapies such as the non-covalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib and chimeric antigen receptor (CAR) T-cell therapy, lisocabtagene maraleucel in the relapsed/refractory setting. Subsequent therapy for relapsed/refractory CLL is based on the type of front-line therapy received and initial response. However, the selection and sequencing of therapies in the relapsed/refractory setting has become increasingly challenging due to the growing number of available options. This session will critically evaluate the data for newer regimens in the relapsed/refractory setting and elucidate the role of each within the treatment paradigm of CLL.

Learning Objectives:

1. Review current guidelines for the treatment of CLL
2. Summarize the data derived from novel treatment strategies for frontline management of CLL
3. Examine the use of the non-covalent BTK inhibitor, pirtobrutinib, and CAR T-cell therapy in relapsed/refractory CLL
4. Design a treatment algorithm for relapsed/refractory CLL

UAN#: 0465-0000-25-036-H01-P

Presenters:

• Jennifer Collins, PharmD, BCOP

Session Description:

This presentation will focus on analyzing the limitations of the current prophylaxis and treatment agents for acute GVHD, as well as exploring new options. Clinical trials utilizing novel agents will be described, and their weaknesses and opportunities highlighted. Discussion will include potential therapeutic drug targets, steroid-free treatment options, biomarker utilization, and sequencing of agents in the steroid-refractory setting.

Learning Objectives:

1. Describe the pathophysiology and outcomes associated with acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplant (HSCT)
2. Recognize the limitations of current preventative and treatment strategies
3. Evaluate clinical data for new preventative and treatment strategies
4. Apply novel options for management of acute GVHD based on patient factors

UAN#: 0465-0000-25-041-L01-P

Presenters:

• Sarah Hayward, PharmD, BCOP
• Erin Hickey Zacholski, PharmD, BCOP
• Jennifer MacDonald, PharmD, BCOP
• Jennifer Stagg, PharmD, BCPS

Session Description:

This session will focus on navigating challenging conversations with patients, including discussion of risk vs benefits of therapy, incorporating an individual's goals of care into the conversation, and creating a safe space to develop rapport and trust with patients. Oncology pharmacists are uniquely equipped to understand intent and toxicities of treatment, and explain these in a way that is easy for patients to understand and absorb. An evidence-based framework will be shared to equip pharmacists during these conversations and facilitate shared decision-making. Concepts will be demonstrated with cases. Pharmacists will learn concrete strategies to help patients make the best decision for their care and improve patient outcomes.

Learning Objectives:

1. Define goals of care conversations and shared clinical decision making
2. Describe barriers to serious illness conversations
3. Apply an evidence-based framework for serious illness conversation into patient care conversations
4. Conduct patient care conversations where shared clinical decision making is utilized
5. Incorporate goals of care into patient education for those receiving palliative intent therapy

UAN#: 0465-0000-25-054-H01-P

Presenter:

• Brooke Adams, PharmD, BCOP

Session Description:

This 75-minute BCOP session will focus on the role and development of adoptive cellular therapies (ACT) for solid tumors. It will summarize the challenges faced in the development of ACT for solid tumors, review recent cellular therapy FDA approvals, and lastly discuss future directions of cellular therapies in the solid tumor pipeline.

Learning Objectives:

1. Discuss the role and mechanisms of adoptive cellular therapy for solid tumor malignancies
2. Describe the challenges in the development of cellular therapies for solid tumor malignancies compared to hematologic malignancies
3. Review the adverse event profile, management, and supportive care for tumor infiltrating lymphocytes (TILs)
4. Summarize the role bi-specific T-cell engaging antibodies in solid tumor malignancies
5. Explain the future directions of cellular therapies in solid tumor malignancies

UAN#: 0465-0000-25-060-H01-P

Presenters:

• Caitlin Harper, PharmD, RPH
• Jennifer Piccolo, PharmD, BCOP

Session Description:

Pharmacogenomics is the study of a patient’s genetic profile and the impact on medication metabolism, safety, and efficacy. Application of pharmacogenomics in oncology allows for medication personalization leading to decreased side effect potential and reduction in treatment related mortality.  This session will discuss the application of key genes impacting cancer and supportive care therapies including models for pharmacogenomics implementation and the data supporting pharmacogenomics guided treatment adjustments to improve patient care of both adult and pediatric patients.

Learning Objectives:

1. Recognize drug-gene pairs with evidence-based guidelines relevant to oncology practice
2. Select an appropriate medication and dose based on gene variants
3. Apply pharmacogenomic results in the context of patient specific factors and goals of therapy to a patient care when recommending adjustments in dose for cancer treatment
4. Compare different pharmacogenomics practice models for application in oncology practice
5. Counsel patients on pharmacogenomic testing results and implications on treatment